Cargando…

Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray

Breast cancer remains the second leading cause of cancer-related death in women despite stratification based on standard hormonal receptor (HR) and HER2 testing. Additional prognostic markers are needed to improve breast cancer treatment. Chromothripsis, a catastrophic genome rearrangement, has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hui, Singh, Rajesh R., Lu, Xinyan, Huo, Lei, Yao, Hui, Aldape, Kenneth, Abraham, Ronald, Virani, Shumaila, Mehrotra, Meenakshi, Mishra, Bal Mukund, Bousamra, Alex, Albarracin, Constance, Wu, Yun, Roy-Chowdhuri, Sinchita, Shamanna, Rashmi Kanagal, Routbort, Mark J., Medeiros, L. Jeffrey, Patel, Keyur P., Broaddus, Russell, Sahin, Aysegul, Luthra, Rajyalakshmi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper: Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355228/ https://www.ncbi.nlm.nih.gov/pubmed/28125801 http://dx.doi.org/10.18632/oncotarget.14802

Ejemplares similares

P729: LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS
por: Hein, Kimberly, et al.
Publicado: (2023)

Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies
por: Chen, Hui, et al.
Publicado: (2015)

Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges
por: Luthra, Rajyalakshmi, et al.
Publicado: (2015)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
por: Zuo, Zhuang, et al.
Publicado: (2022)

Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods
por: Yang, Richard K., et al.
Publicado: (2022)

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing
por: Quesada, Andrés E., et al.
Publicado: (2018)

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2016)

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2017)

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors
por: Mehrotra, Meenakshi, et al.
Publicado: (2017)

Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era
por: Montes-Moreno, Santiago, et al.
Publicado: (2018)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy
por: Quesada, Andrés E., et al.
Publicado: (2021)

Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory
por: Mehrotra, Meenakshi, et al.
Publicado: (2017)

Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Mutations in Early Stage Patients
por: Bolivar, Ana M., et al.
Publicado: (2018)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
por: El Achi, Hanadi, et al.
Publicado: (2021)

Immunocytochemistry of cytology specimens for predictive biomarkers in lung cancer
por: Roy-Chowdhuri, Sinchita
Publicado: (2020)

Relationship between PTEN, DNA Mismatch Repair, and Tumor Histotype in Endometrial Carcinoma: Retained Positive Expression of PTEN Preferentially Identifies Sporadic Non-Endometrioid Carcinomas
por: Djordjevic, Bojana, et al.
Publicado: (2013)

P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
por: Atluri, Himachandana, et al.
Publicado: (2023)

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance
por: Yang, Hui, et al.
Publicado: (2022)

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
por: Zarka, Jabra, et al.
Publicado: (2020)

SDPS-44 RAPID DETECTION OF MUTATIONS IN CSF-CFTNA WITH THE GENEXUS INTEGRATED SEQUENCER
por: Arjuna, Srividya, et al.
Publicado: (2023)

Editorial: Advances in Molecular Cytopathology
por: Vigliar, Elena, et al.
Publicado: (2022)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Consolidative opacity in a patient with acute leukemia
por: Banala, Chaitra, et al.
Publicado: (2022)

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma
por: Siroy, Alan E., et al.
Publicado: (2014)

Clinical Assessment of PTEN Loss in Endometrial Carcinoma: Immunohistochemistry Out-Performs Gene Sequencing
por: Djordjevic, Bojana, et al.
Publicado: (2012)

Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes
por: Tang, Zhenya, et al.
Publicado: (2020)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
por: Ok, Chi Young, et al.
Publicado: (2015)

Intratumoral Morphologic and Molecular Heterogeneity of Rhabdoid Renal Cell Carcinoma: Challenges for Personalized Therapy
por: Singh, Rajesh R., et al.
Publicado: (2015)

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
por: Coleman, Niamh, et al.
Publicado: (2021)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

The transcription factor Foxp1 preserves integrity of an active Foxp3 locus in extrathymic Treg cells
por: Ghosh, Sayantani, et al.
Publicado: (2018)

Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression
por: Gu, Jun, et al.
Publicado: (2015)

Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape
por: Subbiah, Ishwaria M., et al.
Publicado: (2017)

An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma
por: Boddu, Prajwal, et al.
Publicado: (2017)

Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)
por: Mundhada, Shailendra, et al.
Publicado: (2004)

Over-Expression of CYP2E1 mRNA and Protein: Implications of Xenobiotic Induced Damage in Patients with De Novo Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFβ-MYH11
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1k6dscvi3omgb1bf3oh3k5j1f2